Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2023 SABCS

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen


24th SUO Annual Meeting

William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review

Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate

Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment

Stephen J. Freedland, MD, on Managing Prostate Cancer in Transgender Women


ESMO Congress 2023

Tina Cascone, MD, PhD, on NSCLC: Phase III Results on Nivolumab, Chemotherapy, and Surgery

Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab

Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy

Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel

Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy

Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy

Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody

Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023


IASLC 2023 WCLC

Tom E. Stinchcombe, MD, on NSCLC: Strategies for Managing Secondary Primary Disease

Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC

David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC

Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer

Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up

Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers

Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability

Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset

Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease


2023 ASCO Breakthrough Meeting

Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials

Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells

Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing

Desheng Liang, MD, PhD, on Genetic Engineering of Mesenchymal Stem Cells for Cancer Therapy


EHA Hybrid Congress 2023

Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease

Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy

Arnon Kater, MD, PhD on CLL: Recent Data on Venetoclax, Ibrutinib, and Undetectable MRD

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel

Nicholas J. Short, MD, on Acute Lymphoblastic Leukemia: New Analysis of Ponatinib and Blinatumomab

Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab


2023 ASCO Annual Meeting

Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients

Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib

Thierry Conroy, MD, on Rectal Cancer: Long-Term Results on mFOLFIRINOX vs Preoperative Chemoradiation Therapy

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

Guillermo Garcia-Manero, MD, on Myelodysplastic Syndromes: Luspatercept and Epoetin Alfa in Lower-Risk Disease

Narjust Florez, MD, and Roy S. Herbst, MD, on NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival

Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico

Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Georgina V. Long, MD, PhD, on Resected Melanoma: Biomarkers for and Efficacy of Adjuvant Nivolumab vs Placebo

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Narjust Florez, MD, and Heather A. Wakelee, MD, on Early-Stage NSCLC: Phase III Findings From KEYNOTE-671 on Pembrolizumab and Platinum-Based Chemotherapy

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study

Penelope Bradbury, MBChB, on Pleural Mesothelioma: New Results From the IND227 Trial of Cisplatin and Pemetrexed With or Without Pembrolizumab

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision

Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax

James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab

Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial

Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Clifford A. Hudis, MD, on ASCO 2023 Perspectives: The Power of Connecting and Collaborating

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Ajay K. Nooka, MBBS, on High-Risk Myeloma: Data on Carfilzomib, Pomalidomide, and Dexamethasone

Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab


2023 Society of Surgical Oncology International Conference on Surgical Cancer Care

Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis

Kari M. Rosenkranz, MD, on Breast Cancer: Impact of Breast Conservation on Local Recurrence

Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?


AACR Annual Meeting 2023

John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial

Diana Azzam, PhD, on Pediatric Cancers: Efficacy of a Precision Medicine Approach

Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance

Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial

Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities

Harry Klein, PhD, on MatchMiner: An Open-Source AI Precision Medicine Trial Matching Platform

R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin

Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes

Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab

Dario A. Vignali, PhD, on LAG3: The Third Checkpoint Inhibitor

Carmen E. Guerra, MD, MSCE, on Strategies for Equitable Access to Cancer Clinical Trials

Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes

Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response


NCCN 2023 Annual Conference

Michael K. Gibson, MD, PhD, on Metastatic Esophageal Squamous Cell Carcinoma: New First-Line Systemic Treatment Options

Louis B. Nabors, MD, on NCCN Clinical Practice Guidelines in Oncology Updates for CNS Cancers in Adults

Midhun Malla, MD, on Metastatic Colorectal Cancer: Treatment Updates

Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs

Deborah M. Stephens, DO, on CLL/SLL: NCCN Clinical Practice Guidelines in Oncology® Update

Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities

Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges

Elena Ratner, MD, MBA on Sexual Identity and Function in Cancer Survivors

Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies

Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates

Natalie Moryl, MD, on Managing Pain in Patients With Cancer


SGO 2023 Annual Meeting on Women’s Cancer

Shannon N. Westin, MD, MPH, on Endometrial and Ovarian Cancers: New Data on Selumetinib and Olaparib From the SOLAR Trial

Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease

Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial

Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy


2023 ASCO Genitourinary Cancers Symposium

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Potential Predictive Biomarkers of Treatment Efficacy

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Phase III Results on Cabozantinib, Nivolumab, and Ipilimumab

Neeraj Agarwal, MD, on Prostate Cancer: New Data on Talazoparib and Enzalutamide

Aristotelis Bamias, MD, on Urothelial Carcinoma: Final Overall Survival Analysis of Atezolizumab Monotherapy vs Chemotherapy

Paul L. Nguyen, MD, on Prostate Cancer: New Findings on Treatment With Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide

Daniel P. Petrylak, MD, on Prostate Cancer: Latest Data on Pembrolizumab Plus Docetaxel

Alan H. Bryce, MD, on Prostate Cancer: Phase III Results on Rucaparib, Docetaxel, and Androgen Pathway Inhibitor Therapy

Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy

Matt D. Galsky, MD, on Urothelial Carcinoma: New Study Results on Atezolizumab, Platinum, and Gemcitabine

Scott T. Tagawa, MD, on Prostate Cancer: Phase II Results on Ketoconazole, Hydrocortisone, and an Anti-PSMA Antibody

Matt D. Galsky, MD, on Bladder or Upper Urinary Tract Cancer: Extended Follow-up Results From CheckMate 274

Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab

Daniel P. Petrylak, MD, on Urothelial Cancer: Phase II Trial Analysis of Sacituzumab Govitecan-hziy in Metastatic Disease

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy

Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, on Urothelial Carcinoma: Biomarkers of Response to Enfortumab Vedotin-ejfv


2023 ASCO Gastrointestinal Cancers Symposium

Rachna T. Shroff, MD, on Biliary Tract Cancers: Recent Findings on Use of Gemcitabine, Cisplatin, and Nab-paclitaxel

Josep Tabernero, MD, PhD, on Colorectal Cancer: Recent Data on Treatment With Trifluridine and Tipiracil Plus Bevacizumab

Richard S. Finn, MD, on HCC: Tislelizumab vs Sorafenib, and Their Impact on Quality of Life

Nick Pavlakis, PhD, MBBS, on Gastroesophageal Cancer: New Findings on the Use of Regorafenib

Manik A. Amin, MD, on Novel Immune Therapies in GI Cancers: What’s on the Horizon?

Julien Taïeb, MD, PhD, on Treating Colorectal Cancer With Trifluridine and Tipiracil Plus Bevacizumab

Filippo Pietrantonio, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Treatment With Tremelimumab and Durvalumab

Laura A. Dawson, MD, on Hepatocellular Carcinoma and Liver Metastases: Recent Treatment Data on Palliative Radiotherapy

Souya Nunobe, MD, PhD, on Gastric Cancer: 5-Year Follow-up on S-1 Chemotherapy for Stage II Disease

Kohei Shitara, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Zolbetuximab Plus mFOLFOX6

Laura A. Dawson, MD, on Hepatocellular Carcinoma: Phase III Data on Sorafenib vs Stereotactic Body Radiation Therapy

Zev A. Wainberg, MD, on Pancreatic Ductal Adenocarcinoma: Recent Findings on NALIRIFOX vs Nab-paclitaxel Plus Gemcitabine


2022 ASH Annual Meeting and Exposition

Paolo F. Caimi, MD, on DLBCL: Outcomes After R-ICE Chemoimmunotherapy

Tycel J. Phillips, MD, on Mantle Cell Lymphoma: New Findings on Glofitamab Monotherapy

Eunice S. Wang, MD, on AML: Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes

Tomohiro Aoki, MD, PhD, on the Spatial Tumor Microenvironment and Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma

Joseph Schroers-Martin, MD, on Posttransplant Lymphoproliferative Disorders: Tumor Microenvironment Determinants of Immunotherapy Response

Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD: New Findings on How the IRF4 Gene Shapes Tumor Immunity in Follicular Lymphoma

Elias Jabbour, MD, on CML and ALL: Olverembatinib Overcomes Ponatinib Resistance

Jorge E. Cortes, MD, on CML: Efficacy and Safety of Vodobatinib

Jia Ruan, MD, PhD, on Mantle Cell Lymphoma: Phase II Findings on Acalabrutinib/Lenalidomide/Rituximab

Eva Hoster, PhD, on Mantle Cell Lymphoma: Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Kathryn R. Tringale, MD, on Primary CNS Lymphoma: Initial Treatment Response in More Than 500 Patients

Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

Smita Bhatia, MD, MPH: Some Clonal Mutations May Predict Therapy-Related Myeloid Neoplasms

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Anand P. Jillella, MD, on Acute Promyelocytic Leukemia: A Simplified Patient Care Strategy to Decrease Early Deaths

Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends

Francesco Maura, MD, on Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy

Jiye Liu, PhD, on Multiple Myeloma: Genome-Wide CRISPR-Cas9 Screening Identifies KDM6A as a Modulator of Daratumumab Sensitivity

Irene Roberts, MD, on Leukemogenesis in Infants With Trisomy 21

Mark R. Litzow, MD, on ALL: Consolidation Therapy With Blinatumomab Improves Overall Survival

Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

Paul G. Richardson, MD, on Multiple Myeloma: Mezigdomide Plus Dexamethasone in Relapsed and Refractory Disease

Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling

Advertisement

Advertisement



Dec
09
Today In Oncology
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside